Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.109989 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Mark Kristof Farkas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Center, Semmelweis University, Bókay János u. 53-54, Budapest 1083, Hungary. Electronic address: kristofm.farkas@gmail.com. Hauptthemen laut MEDLINE: Anticonvulsants, Executive Function, Lacosamide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma, UCB Pharma Ltd.
Abstract (Originalsprache)
OBJECTIVES: To evaluate long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide (LCM) treatment in pediatric patients (≥1 month to 75 % of patients by both physicians and caregivers. Treatment-emergent adverse events (TEAEs) were reported by 749 (82.8 %) patients, most commonly pyrexia (18.9 %), upper respiratory tract infection (18.6 %), nasopharyngitis (16.2 %), vomiting (15.7 %), and somnolence (11.8 %). The most common drug-related TEAEs were somnolence (8.5 %), dizziness (7.6 %), and vomiting (5.4 %). Behavioral and emotional function was generally stable in patients 1.5-5 years of age and slightly improved in patients ≥6 years of age, and executive functioning was stable in patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Center, Semmelweis University, Bókay János u. 53-54, Budapest 1083, Hungary. Electronic address: kristofm.farkas@gmail.com.
- Dnipro City Pediatric Clinical Hospital, 5 Ivana Akinfieva St, Dnipro 49027, Ukraine. Electronic address: iryna.maked@gmail.com.
- UCB Pharma, Morrisville, NC, United States. Electronic address: Cynthia.Beller@ucb.com.
- UCB Pharma, Agiou Dimitriou 63, Alimos 17456, Greece. Electronic address: Dimitrios.Bourikas@ucb.com.
- UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium. Electronic address: Christine.Delaloge@ucb.com.
- UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium. Electronic address: Svetlana.Dimova@ucb.com.
Förderung
- UCB Pharma
- UCB Pharma Ltd
Zitieren
APA
Farkas, M. K., Makedonska, I., Beller, C., Bourikas, D., de la Loge, C., Dimova, S., Floricel, F., McClung, C., Moseley, B., Therriault, S., & Pina-Garza, J. E. (2024). Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109989
Vancouver
Farkas MK, Makedonska I, Beller C, Bourikas D, de la Loge C, Dimova S, et al. Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109989
BibTeX
@article{Farkas2024,
author = {Farkas, Mark Kristof and Makedonska, Iryna and Beller, Cynthia and Bourikas, Dimitrios and de la Loge, Christine and Dimova, Svetlana and Floricel, Florin and McClung, Carrie and Moseley, Brian and Therriault, Sheila and Pina-Garza, Jesus Eric},
title = {Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.109989}
}
EUVIMED